Darmiyan

Darmiyan operates at the intersection of neurotechnology, medical imaging, clinical decision support, and digital diagnostics. Its differentiation is a disease-specific workflow rather than a general-purpose imaging model: BrainSee combines routine brain MRI data with cognitive test scores to estimate the likelihood that a patient with mild cognitive impairment will progress to Alzheimer's dementia. DarmiScope provides the underlying virtual-microscope concept, analyzing tissue architecture at the voxel level. The company reports approximately 90% accuracy for five-year prognosis in a blind evaluation of 411 cases with five years of follow-up, although independent validation scope and commercial adoption remain important considerations. Relative to broad medical-imaging AI companies, Darmiyan's positioning is narrower and more clinically focused, centered on neurodegeneration prognosis rather than radiology across multiple specialties. FDA authorization for BrainSee and participation in the Medicare GUIDE program provide stronger clinical and reimbursement relevance than an unregulated research platform, while the company's approximately 11-to-50 employee profile suggests a specialized scale rather than a large commercial footprint.

Darmiyan's trajectory shows a progression from foundational neuroscience research to regulated clinical software and care-program deployment. The company was founded in 2016, followed by a $120,000 Pre-Seed round and $800,000 in Non-Equity Assistance in 2017. It then raised $3.7 million in a 2017 Seed round, an additional Seed round with no disclosed amount in 2018, and $6,432,250 in a 2020 Seed round led by Eisai. The latest disclosed financing was a $3,536,249 Venture Round on Oct 17, 2023, bringing reported total funding to $14,588,499 across six rounds. The major operating inflection point came in 2024, when BrainSee received FDA approval and the company began participating in the Medicare GUIDE program through several care partners. In 2025, Darmiyan received approval for a post-market surveillance study and was selected by the California Association of Health Facilities as a preferred provider. Its current employee range remains approximately 11 to 50 people, with six identified current positions, suggesting measured scaling while building clinical evidence, partnerships, and distribution rather than pursuing rapid headcount expansion.